ARS Pharmaceuticals (SPRY) Projected to Post Earnings on Tuesday

Key Points

• ARS Pharmaceuticals (NASDAQ:SPRY) is set to announce its Q2 2025 earnings on August 5th, with analysts predicting a loss of ($0.42) per share and revenue of $12.92 million.
• The company reported ($0.35) earnings per share in its last quarterly results, matching analyst expectations, and achieved revenue of $7.97 million.
• Recent insider trading saw significant stock sales, with insiders selling 1,043,118 shares valued at over $18 million in the last three months.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect ARS Pharmaceuticals to post earnings of ($0.42) per share and revenue of $12.92 million for the quarter.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, meeting the consensus estimate of ($0.35). ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. The business had revenue of $7.97 million for the quarter, compared to the consensus estimate of $7.48 million. On average, analysts expect ARS Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ARS Pharmaceuticals Price Performance

Shares of SPRY traded down $0.50 during trading hours on Friday, hitting $17.18. 1,181,354 shares of the stock were exchanged, compared to its average volume of 1,515,884. The stock's 50-day moving average price is $16.39 and its two-hundred day moving average price is $14.06. The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.74 and a current ratio of 11.00. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -107.37 and a beta of 0.90. ARS Pharmaceuticals has a 12-month low of $8.91 and a 12-month high of $18.90.

Insider Buying and Selling

In other news, insider Alexander A. Fitzpatrick sold 102,969 shares of ARS Pharmaceuticals stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total transaction of $1,451,862.90. Following the sale, the insider owned 89,613 shares of the company's stock, valued at approximately $1,263,543.30. The trade was a 53.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder James E. Flynn sold 740,149 shares of the stock in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $18.46, for a total value of $13,663,150.54. Following the completion of the transaction, the insider owned 4,887,254 shares of the company's stock, valued at $90,218,708.84. The trade was a 13.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,043,118 shares of company stock worth $18,024,863 over the last quarter. Corporate insiders own 33.50% of the company's stock.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several large investors have recently modified their holdings of SPRY. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of ARS Pharmaceuticals by 13.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 279,840 shares of the company's stock worth $3,520,000 after purchasing an additional 32,526 shares during the period. Royal Bank of Canada lifted its position in shares of ARS Pharmaceuticals by 1,075.3% during the first quarter. Royal Bank of Canada now owns 18,547 shares of the company's stock worth $234,000 after purchasing an additional 16,969 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of ARS Pharmaceuticals during the first quarter worth about $140,000. Institutional investors and hedge funds own 68.16% of the company's stock.

Analysts Set New Price Targets

Separately, Wall Street Zen cut shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, July 26th. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, ARS Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.